WuXi Bio expands US presence; FujiFilm boosts autoinjector services; SpectronRx to make prostate cancer radioligand

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

WuXi Bi­o­log­ics is ex­pand­ing its fa­cil­i­ty in Worces­ter, MA, by 12,000 liters for com­mer­cial drug sub­stance pro­duc­tion to a to­tal of 36,000 liters. An­nounced on Mon­day, con­struc­tion of the 189,500 square-foot fa­cil­i­ty is un­der­way, which was orig­i­nal­ly planned to on­ly house 24,000 liters. The site will be op­er­a­tional in 2025, with a GMP re­lease in 2026, adding 200 new jobs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.